Durable suppression of disease activity by alemtuzumab in the absence of continuous treatment over 6 years in patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy (CARE-MS II)

C. LaGanke, J. De Seze, M. S. Freedman, M. Habek, R. M. M. Hupperts, V. Limmroth, R. A. L. Macdonell, K. W. Selmaj, D. H. Margolin, K. Thangavelu, E. Havrdova

Research output: Contribution to journalConference Abstract/Poster in journalAcademic

Original languageEnglish
Pages (from-to)327-328
Number of pages2
JournalMultiple Sclerosis Journal
Volume22
Publication statusPublished - Sep 2016

Cite this